Healthcare AI pilots are relatively easy to launch. Moving them into reliable, scalable production workflows is much harder.

A pilot can prove that an AI system is capable of performing a specific task. But production requires something broader: reliable data, workflow integration, human oversight, validation, governance, security, user adoption, monitoring, and measurable business value.

In other words, healthcare AI pilots often fail to reach production not because the model cannot perform the task, but because technical performance is only one part of implementation. The operational environment around the AI matters just as much.

This distinction is particularly important in pharmaceutical and regulated Life Sciences environments, where faster output cannot come at the expense of quality, traceability, review, or accountability.

A Harvard Business Review (HBR) Analytic Services white paper sponsored by Salesforce highlights this gap. Many organizations develop AI use cases but lack a clear path from experimentation to implementation, where integration with existing systems, user training, governance, and ongoing performance management become essential.

So, what prevents a promising AI pilot from becoming a production system?

Why a successful AI pilot is not the same as production

An AI experiment asks whether an idea might work. A proof of concept tests whether the technology can perform a defined task. A pilot goes further by applying that capability to a limited but representative workflow.

Production asks a different set of questions.

Can the AI perform reliably across real data and users? Can experts review and control its output? Can the organization trace what happened? Can the workflow manage exceptions? Can performance be monitored over time? And, ultimately, does it create measurable value?

A strong pilot result therefore provides evidence of technical feasibility, not production readiness.

For example, generating a high-quality regulatory draft from carefully prepared source material demonstrates useful capability. But it does not prove that the same workflow will perform consistently across different studies, data sources, document types, users, and unexpected cases.

That is where many AI initiatives encounter problems.

Why healthcare AI pilots fail

The gap between pilot and production usually extends far beyond model performance. In practice, several factors tend to determine whether an AI use case can make the transition.

1. The pilot solves an AI problem, not a business problem

AI projects often start with:

Where can we use AI?

A better question is:

What problem are we trying to solve?

For example, a regulatory team might need to reduce repetitive data-to-text work, shorten review cycles, improve consistency across documents, or handle submission peaks without continually increasing resources.

Those are defined problems that can be measured against a baseline.

Without one, however, an impressive AI demonstration can remain just that: a demonstration rather than a useful production workflow.

The HBR Analytic Services report makes a similar point when discussing vendor evaluation. Organizations should start with the problem they are trying to solve rather than selecting technology simply because AI is part of the offering.

2. Pilot data does not represent production data

Once the business problem is clear, the next challenge is usually data.

Healthcare and Life Sciences organizations rarely suffer from a lack of information. The difficulty is making that information usable.

The HBR report describes healthcare data as highly dispersed, inconsistent, often unstructured, and frequently stored across legacy systems that do not communicate effectively.

A pilot can hide that complexity by using selected, complete, or manually prepared data. Production cannot.

Regulated workflows may need to handle different file formats, changing source documents, clinical datasets, tables, listings, figures, document versions, metadata, and approved reference information.

As a result, the question is not only whether the AI works with data. It is whether it works with the data environment the organization actually has.

3. AI is not integrated into the real workflow

Even when the data is available, integration can become the next obstacle.

A model can make one task faster while making the overall process more complicated.

Imagine an AI tool generates a regulatory draft in minutes, but users still need to extract information manually, upload files, transfer the output into another system, verify every statement separately, and recreate the normal review and approval process.

The generation step improved. The workflow may not have.

For AI to create value in production, it needs to fit into the processes around generation, including access to source information, review, validation, approvals, version management, and downstream systems.

4. Human oversight is treated as a final step

Integration alone is not enough, particularly in regulated workflows.

Human oversight is sometimes treated as something that can simply be added before deployment: AI generates the content, a person approves it, and the requirement is considered covered.

In practice, meaningful oversight requires more.

Organizations need to define who reviews the output, what they are expected to verify, what evidence they receive, when escalation is required, and who remains responsible for the final decision.

Human oversight should therefore be designed into the workflow from the beginning, rather than added as a final checkbox.

5. Governance and validation arrive too late

The same principle applies to governance and validation.

During a pilot, teams naturally concentrate on whether the model produces acceptable results. But once AI enters production, additional questions become unavoidable.

Who can use the system? What information can it access? How are changes controlled? How are outputs traced? What happens when the system fails? What needs to be validated? Who owns ongoing monitoring?

The answers depend on the intended use, risk, organizational procedures, and applicable requirements. Not every AI use case requires exactly the same controls.

The important point is to define those requirements before scaling, rather than discovering them after deployment.

6. The pilot measures speed instead of value

Even if all of these controls are in place, the business case still needs to hold.

A faster first draft is easy to demonstrate. It does not necessarily mean the workflow delivers ROI.

If experts spend the saved time correcting content, checking unsupported statements, resolving inconsistencies, or managing exceptions, part of the apparent benefit disappears.

For that reason, production evaluation should measure the complete workflow, including reviewer effort, correction rates, review cycles, quality, traceability, adoption, and operational reliability.

As with regulatory AI ROI more broadly, efficiency should be evaluated alongside quality, compliance, and strategic value.

7. Users are involved too late

Finally, even a technically strong and well-controlled system can fail if people do not use it.

The HBR report emphasizes the role of change management and recommends involving frontline users in the design of AI-enabled workflows.

This is particularly relevant in pharmaceutical environments, where regulatory affairs, medical writing, clinical operations, quality, data, security, and other teams may all interact with the same workflow.

Involving these users early can reveal practical problems that model testing alone will never identify.

How to move AI from pilot to production

Understanding why pilots fail also provides a roadmap for moving them forward.

Instead of treating production as the stage that comes after a successful pilot, organizations should consider production requirements while the pilot is still being designed.

1. Start with a measurable workflow problem

Define the current process, users, inputs, outputs, bottlenecks, review effort, cycle time, quality issues, and costs.

The pilot should then demonstrate improvement against this baseline.

2. Define the intended use

Specify what the AI will do, what it will not do, which sources it can use, and where human judgment remains required.

This creates clear boundaries for testing, validation, governance, and performance measurement.

3. Build around trusted data

Identify approved sources and define requirements for data quality, access, completeness, and traceability.

Importantly, testing should include difficult cases too, such as missing inputs, conflicting information, changing formats, and unexpected source material.

4. Design human oversight into the workflow

Define review points, approval responsibilities, escalation paths, exception handling, and the circumstances in which users should reject or override AI output.

Reviewers should also have enough information to independently assess the output rather than simply approve it.

5. Define production success before scaling

At this point, organizations should look beyond model accuracy.

Production metrics should cover quality and correction rates, end-to-end workflow time, reviewer effort, traceability, reliability, exceptions, user adoption, governance controls, and business value.

This is important because faster generation only matters if the broader workflow improves.

6. Test the complete workflow

Production readiness involves more than testing the model.

Organizations also need to evaluate integrations, permissions, workflow logic, security, auditability, review processes, applicable validation requirements, and exception handling under conditions that resemble actual use.

7. Scale gradually and keep monitoring

Finally, moving into production does not need to mean immediate organization-wide deployment.

AI can be scaled in controlled stages, for example by document type, study, team, or workflow. This gives organizations an opportunity to compare actual production performance against the original baseline and identify problems that only emerge with greater volume or variability.

And importantly, monitoring should continue after deployment. Production is not the end of the AI lifecycle.

What changes when AI reaches production?

The transition becomes clearer when pilot and production environments are compared directly:

Pilot	Production	Why it matters
Selected data	Representative real-world data	Production must handle normal variation
Limited users	Real users and roles	Adoption and usability affect results
Standalone testing	Integrated workflow	Value depends on the complete process
Informal review	Defined human oversight	Review must be repeatable and accountable
Model testing	Risk-based workflow validation	The system around the model also matters
Technical metrics	Operational and business metrics	Accuracy alone does not prove value
Controlled cases	Exceptions and fallback processes	Production must handle failure
Short evaluation	Ongoing monitoring	Performance can change
Project team	Defined governance and ownership	Someone must manage the system long term

In other words, production readiness is an operational capability, not simply a model performance threshold.

How to know if an AI pilot is ready for production

Before scaling, organizations should be able to answer questions such as:

• Is the intended use clearly defined?
• Has the workflow demonstrated measurable value?
• Has it been tested on representative real-world cases?
• Are data requirements understood?
• Can outputs be traced to approved sources where required?
• Are human review and approval responsibilities clear?
• Have likely exceptions and failure scenarios been tested?
• Can the AI integrate into the actual workflow?
• Are security and privacy requirements addressed?
• Are applicable validation requirements defined?
• Are intended users trained and adopting the workflow?
• Are production metrics and monitoring responsibilities established?
• Is there a controlled process for future changes?

Not every unresolved issue necessarily prevents deployment. However, risks should be visible, understood, owned, and managed rather than discovered accidentally once the system is already in use.

Common mistakes when scaling AI

Even with a clear production strategy, several mistakes can undermine an otherwise promising AI pilot:

• Scaling because the demo looked impressive
• Measuring only model accuracy or generation speed
• Ignoring downstream review effort
• Assuming clean pilot data represents production data
• Treating human review as a final checkbox
• Involving quality, compliance, security, or end users too late
• Scaling too many use cases at once
• Treating deployment as the end of the project

These mistakes have something in common. They focus on the AI while underestimating the environment required around it.

How Narrativa approaches production-ready AI workflows

Narrativa develops agentic AI solutions designed for regulated Life Sciences workflows, including clinical study reports, patient narratives, regulatory documentation, data interpretation, and content validation.

Rather than treating generation as an isolated prompt, production-oriented workflows can combine approved source information, standardized processes, traceability, audit trails, role-based access, human review, and quality controls.

This approach helps move AI from experimentation to real-world use by improving consistency, source verification, review, and control.

However, technology alone is not enough. Successful deployment also depends on intended use, data readiness, validation requirements, organizational processes, governance, and user adoption.

For healthcare AI pilots, proving that AI can perform a task is only the first milestone. The real goal is proving that the entire workflow can operate reliably, measurably, and sustainably when AI becomes part of everyday work.

FAQs

Why do healthcare AI pilots fail?

Healthcare AI pilots often struggle to reach production because they test technical capability without addressing operational requirements. Production also requires representative data, workflow integration, human oversight, governance, security, user adoption, exception handling, and monitoring. A successful model demonstration therefore does not automatically prove that the complete workflow is ready to scale.

What is the difference between an AI pilot and production AI?

An AI pilot tests whether technology can perform a task under limited conditions. Production AI operates with real data, users, systems, controls, and business processes. As a result, production requires additional capabilities such as integration, governance, monitoring, human oversight, exception management, and evidence of sustainable operational value.

How do you move an AI pilot into production?

Start with a measurable workflow and clearly defined intended use. Then establish data requirements, human oversight, production metrics, governance, integration, security, validation needs, and exception handling. Test the complete workflow using representative cases before scaling gradually and monitoring actual performance.

How do you know if an AI pilot is ready for production?

An AI pilot is closer to production readiness when its intended use is defined, results remain consistent across representative cases, data requirements are understood, users can review outputs, exceptions have been tested, relevant controls are established, and performance can be monitored. It should also demonstrate measurable improvement over the existing workflow.

Does production AI require human oversight?

The appropriate level of human oversight depends on the intended use, risk, organizational procedures, and applicable requirements. In regulated Life Sciences workflows involving scientific, clinical, regulatory, or quality judgment, qualified professionals should retain responsibility for relevant decisions and final approval.